Kura Oncology Overview
- Founded
- 2014
- Status
- Public
- Employees
- 83
- Stock Symbol
- KURA
- Investments
- 1
- Share Price
- $29.73
- (As of Wednesday Closing)
Kura Oncology General Information
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 12730 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Kura Oncology Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.73 | $32.80 | $6.35 - $43.00 | $1.96B | 66M | 867K | -$1.63 |
Kura Oncology Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 1,400,909 | 380,451 | 352,882 | 368,535 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (84,391) | (67,234) | (62,636) | (35,267) |
| Net Income | (81,331) | (63,140) | (60,447) | (35,434) |
| Total Assets | 339,567 | 241,972 | 182,379 | 95,851 |
| Total Debt | 15,426 | 7,500 | 7,500 | 7,098 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kura Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.
Request a free trialKura Oncology Executive Team (15)
Kura Oncology Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Diane Parks | Self | Board Member | 000 0000 |
| Faheem Hasnain | Self | Board Member | 000 0000 |
| Mary Szela | Self | Board Member | 000 0000 |
| Robert Hoffman | Self | Board Member | 000 0000 |
| Steven Stein MD | Self | Board Member | 000 0000 |
Kura Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKura Oncology Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000000 | 06-Mar-2015 | 000000000000000000 | Holding Companies |